data analysis quality control strains s pneumoniae atcc 49619 (ATCC)
ATCC is a verified supplier 
ATCC manufactures this product 
99
Structured Review
ATCC
data analysis quality control strains s pneumoniae atcc 49619
Data Analysis Quality Control Strains S Pneumoniae Atcc 49619, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 2949 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/data+analysis+quality+control+strains+s+pneumoniae+atcc+49619/Streptococcus+pneumoniae+(Klein)+Chester/pm41277341-34-79-86
Average 99 stars, based on 2949 article reviews
Data Analysis Quality Control Strains S Pneumoniae Atcc 49619, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 2949 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/data+analysis+quality+control+strains+s+pneumoniae+atcc+49619/Streptococcus+pneumoniae+(Klein)+Chester/pm41277341-34-79-86
Average 99 stars, based on 2949 article reviews
data analysis quality control strains s pneumoniae atcc 49619 - by Bioz Stars,
2026-09
99/100 stars
Images
Related Articles
Control:Article Title: Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Türkiye: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. Article Snippet: .. The antibiotics with high-dose availability assessed in this way included: amoxicillin (0.75–1 g oral, 3×daily), amoxicillin/clavulanic acid (0.875 g amoxicillin/0.125 g clavulanic acid oral, 3×daily), ampicillin (2 g intravenous [IV], 4×daily), penicillin (2.4 g IV, 2 MU 4–6×daily), ceftriaxone (2 g IV, 2×daily), clarithromycin (0.5 g oral, 2×daily), erythromycin (1 g oral or IV, 4×daily), levofloxacin (0.75 g oral 2×daily, or 0.4 g IV 3×daily) and trimethoprim/sulfamethoxazole (0.24 g trimethoprim/1.2 g sulfamethoxazole oral or IV, 2×daily).16 Quality control and Article Title: Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Ukraine: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. Article Snippet: .. To fully assess antibiotics where high-dose therapies are available, susceptibility using EUCAST criteria was also calculated by combining percentage susceptible and susceptible, increased exposure into the susceptible category.11 The antibiotics with high-dose availability assessed in this way included the following: amoxicillin (0.75–1 g oral, 3× daily), amoxicillin/clavulanic acid (0.875 g amoxicillin/0.125 g clavulanic acid oral, 3× daily), ampicillin [2 g intravenous (IV), 4×daily], penicillin (2.4 g IV, 2 MU 4–6× daily), ceftriaxone (2 g IV, 2× daily), clarithromycin (0.5 g oral, 2× daily), erythromycin (1 g oral or IV, 4× daily), levofloxacin (0.75 g oral 2× daily, or 0.4 g IV 3× daily) and trimethoprim/sulfamethoxazole (0.24 g trimethoprim/1.2 g sulfamethoxazole oral or IV, 2× daily).11 Quality control and Article Title: Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Italy and Spain: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. Article Snippet: .. Quality control and Article Title: Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Pakistan: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. Article Snippet: .. To fully assess antibiotics where high-dose therapies are available, susceptibility using EUCAST criteria was also calculated by combining percentage susceptible and susceptible, increased exposure into the susceptible category as well as dose-dependent PK/ PD breakpoints.15,16 The antibiotics with high-dose availability assessed in this way were as follows: amoxicillin (0.75–1 g oral, 3× daily), amoxicillin/clavulanic acid (0.875 g amoxicillin/0.125 g clavulanic acid oral, 3× daily), ampicillin (2 g intravenous [IV], 4× daily), penicillin (2.4 g IV, 2 MU 4–6× daily), ceftriaxone (2 g IV, 2× daily), clarithromycin (0.5 g oral, 2× daily), erythromycin (1 g oral or IV, 4× daily), levofloxacin (0.75 g oral 2× daily or 0.4 g IV 3× daily) and trimethoprim/sulfamethoxazole (0.24 g trimethoprim/1.2 g sulfamethoxazole oral or IV, 2× daily).15 Quality control and Article Title: Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in India: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. Article Snippet: .. To fully assess antibiotics where high-dose therapies are available, susceptibility using EUCAST criteria was also calculated by using the susceptible, increased exposure breakpoints (former intermediate category) as well as dose-dependent PK/PD breakpoints.18 Quality control and Article Title: Results from the Survey of Antibiotic Resistance (SOAR) 2015-17 in Pakistan: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. Article Snippet: .. To fully assess antibiotics where high-dose therapies are available, susceptibility using EUCAST criteria was also calculated by combining percentage susceptible and percentage intermediate (susceptible, increased exposure) into the susceptible category.11 The antibiotics with high dose availability assessed in this way were as follows: amoxicillin (0.75–1 g oral, 3%daily), amoxicillin/clavulanic acid (0.875 g amoxicillin/ 0.125 g clavulanic acid oral, 3%daily), ampicillin (2 g IV, 4%daily), penicillin (2.4 g IV, 2 MU 4–6%daily), ceftriaxone (2 g IV, 2%daily), clarithromycin (0.5 g oral, 2%daily), erythromycin (1 g oral or IV, 4%daily), levofloxacin (0.75 g oral, 2%daily; or 0.4 g IV, 3%daily) and trimethoprim/sulfamethoxazole (0.24 g trimethoprim/1.2 g sulfamethoxazole oral or IV, 2%daily).11 Quality control and data analysis Quality control strains S. pneumoniae ATCC 49619, |